Brief: Ascletis To Submit IND To U.S. FDA For ASC37 Oral Tablets In 2nd Qtr Of 2026
30/11/2025 10:25
Nov 30 (Reuters) - Ascletis Pharma Inc 1672.HK: EXPECTS TO SUBMIT INVESTIGATIONAL NEW DRUG APPLICATION (IND)TO U.S. FDA FOR ASC37 ORAL TABLETS IN SECOND QUARTER OF 2026 Source text Further company coverage: 1672.HK (Reporting by Hong Kong newsroom) ((donny.kwok@thomsonreuters.com; +852 3462 7745;))
Recent news on Ascletis Pharma
See all newsFactbox: Race to launch weight-loss pill heats up as Novo wins UK approval
Brief: Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
Factbox: Race to launch weight-loss pill heats up as Lilly wins US approval
Brief: Ascletis Pharma FY Loss Attributable Rmb359.9 Million
Brief: Ascletis Pharma Expects To Submit IND Application To U.S. FDA For ASC39 In Q3 2026